Stockreport

Candel Therapeutics: Potentially The Next Exciting Oncology Story [Seeking Alpha]

Candel Therapeutics, Inc.  (CADL) 
PDF CAN-2409's strong phase III prostate cancer results, RMAT designation, and 60% approval odds support my bullish thesis; lung and pancreatic cancer indications add furth [Read more]